共 50 条
Faecal microbiota transplantation: a regulatory hurdle?
被引:22
|作者:
Verbeke, Frederick
[1
]
Janssens, Yorick
[1
]
Wynendaele, Evelien
[1
]
De Spiegeleer, Bart
[1
]
机构:
[1] Univ Ghent, Drug Qual & Registrat DruQuaR Grp, Fac Pharmaceut Sci, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
来源:
关键词:
Regulatory affairs;
Faecal microbiota transplantation;
C. difficile Infection;
Pseudomembranous colitis;
CLOSTRIDIUM-DIFFICILE INFECTION;
RANDOMIZED CLINICAL-TRIAL;
HEALTH-CARE-SYSTEM;
OPEN-LABEL;
METAANALYSIS;
DISEASE;
BURDEN;
VANCOMYCIN;
THERAPY;
FROZEN;
D O I:
10.1186/s12876-017-0687-5
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation. Currently, regulatory harmonization is completely lacking and authorities apply non-existing to most stringent requirements. A regulatory approach for faecal microbiota transplantation could be inserting faecal microbiota transplantation in the gene-, cell-and tissue regulations, including the hospital exemption system in the European Advanced Therapy Medicinal Products regulation, providing a pragmatic and efficacy-risk balanced approach and granting all patients as a matter of principle access to this therapy.
引用
收藏
页数:11
相关论文